According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
TACE first ,and more TACE could be performed when it is necessary.
Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
RECRUITING1-year survival rate
1-year survival rate assessed by Kaplan-Meier analysis
Time frame: at 1 year after enrolled
Time to progression
Time to progression assessed by independent radiologic review according to mRECIST criteria
Time frame: at 12 weeks and up to 2 years after enrolled
Progression free survival
Progression free survival assessed by independent radiologic review according to mRECIST criteria
Time frame: at 12 weeks and up to 2 years after enrolled
Objective response rate
Objective response rate assessed by independent radiologic review according to mRECIST criteria
Time frame: at 12 weeks and up to 2 years after enrolled
Disease control rate
Disease control rate assessed by independent radiologic review according to mRECIST criteria
Time frame: at 12 weeks and up to 2 years after enrolled
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.